Chimeric antigen receptor

Steven Lee; Roy Bicknell; Michaela Sharpe; Natalie Mount

Chimeric antigen receptor

Steven Lee (Inventor), Roy Bicknell (Inventor), Michaela Sharpe (Inventor), Natalie Mount (Inventor)

Research output: Patent

Abstract

The present invention is directed to a nucleic acid molecule comprising a polynucleotide sequence encoding a chimeric antigen receptor comprising (a) an anti-CLEC14A binding domain, (b) a transmembrane domain and (c) an intracellular signalling domain; wherein said anti-CLEC14A binding domain is capable of binding to the C- type lectin domain of CLEC14A. The invention further provides a chimeric antigen receptor encoded by the nucleic acid molecule, a vector comprising the nucleic acid molecule, a cell comprising the nucleic acid molecule, vector or CAR and the therapeutic use of the nucleic acid, vector or cell, particularly in treating CLEC14A expressing conditions.

Original language	English
Patent number	WO2017158337
Publication status	Published - 21 Sept 2017

Cite this

@misc{02273c97ac2741b583f405ab17825436,

title = "Chimeric antigen receptor",

abstract = "The present invention is directed to a nucleic acid molecule comprising a polynucleotide sequence encoding a chimeric antigen receptor comprising (a) an anti-CLEC14A binding domain, (b) a transmembrane domain and (c) an intracellular signalling domain; wherein said anti-CLEC14A binding domain is capable of binding to the C- type lectin domain of CLEC14A. The invention further provides a chimeric antigen receptor encoded by the nucleic acid molecule, a vector comprising the nucleic acid molecule, a cell comprising the nucleic acid molecule, vector or CAR and the therapeutic use of the nucleic acid, vector or cell, particularly in treating CLEC14A expressing conditions.",

author = "Steven Lee and Roy Bicknell and Michaela Sharpe and Natalie Mount",

year = "2017",

month = sep,

day = "21",

language = "English",

type = "Patent",

note = "WO2017158337",

}

TY - PAT

T1 - Chimeric antigen receptor

AU - Lee, Steven

AU - Bicknell, Roy

AU - Sharpe, Michaela

AU - Mount, Natalie

PY - 2017/9/21

Y1 - 2017/9/21

N2 - The present invention is directed to a nucleic acid molecule comprising a polynucleotide sequence encoding a chimeric antigen receptor comprising (a) an anti-CLEC14A binding domain, (b) a transmembrane domain and (c) an intracellular signalling domain; wherein said anti-CLEC14A binding domain is capable of binding to the C- type lectin domain of CLEC14A. The invention further provides a chimeric antigen receptor encoded by the nucleic acid molecule, a vector comprising the nucleic acid molecule, a cell comprising the nucleic acid molecule, vector or CAR and the therapeutic use of the nucleic acid, vector or cell, particularly in treating CLEC14A expressing conditions.

AB - The present invention is directed to a nucleic acid molecule comprising a polynucleotide sequence encoding a chimeric antigen receptor comprising (a) an anti-CLEC14A binding domain, (b) a transmembrane domain and (c) an intracellular signalling domain; wherein said anti-CLEC14A binding domain is capable of binding to the C- type lectin domain of CLEC14A. The invention further provides a chimeric antigen receptor encoded by the nucleic acid molecule, a vector comprising the nucleic acid molecule, a cell comprising the nucleic acid molecule, vector or CAR and the therapeutic use of the nucleic acid, vector or cell, particularly in treating CLEC14A expressing conditions.

M3 - Patent

M1 - WO2017158337

ER -

Chimeric antigen receptor

Abstract

Fingerprint

Cite this